**Annex 1: Distribution of study subjects according to the risk factors for exposure to SARS-CoV-2, Tunis, March-April2021**

|  |  |  |
| --- | --- | --- |
| **Variables** | **N** | **%** |
| **Respect of preventive measures (n=1663)** |  |  |
| Frequently | 1138 | 68.4 |
| Occasionally/ Never | 525 | 31.6 |
| **Travelling abroad since December, 2019 (n=1676)** |  |  |
| Yes | 52 | 3.1 |
| No | 1624 | 96.9 |
| **Contact with a COVID-19 case within the household (n=1676)** |  |  |
| Yes | 1198 | 71.5 |
| No | 478 | 28.5 |
| **Seeking care in a health facility since the beginning of the COVID-19 pandemic in Tunisia (Mars 2020) (n=1667)** |  |  |
| Yes | 909 | 54.5 |
| No | 758 | 45.5 |
| **Means of transport used (n=1632)** |  |  |
| Car | 607 | 37.2 |
| Public transport | 441 | 27.0 |
| Bicycle/motorcycle | 14 | 0.9 |
| Different means of transport | 176 | 10.8 |
| None | 394 | 24.1 |

**Annex 2**: **Some previous SARS-CoV-2 seroprevalence surveys among general public before the beginning of mass vaccination campaigns**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Country | References | Population size | Study period | Antibodies | Antibody detection tests | Seroprevalence (%) |
| France | Le Vu et al[1] | 2879 | May 2020 | IgG anti-S IgG anti-N pseudo-neutralizing antibodies | In-house test (LuLISA) | 4.9 |
| UAEa | Alsuwaidi et al[2] | 8831 | July August 2020 | IgG anti-S | Commercial test (Diasorin) | 10.4 |
| Peru, Iquitos | Álvarez-Antonio et al[3] | 716 | July 2020 | IgG/IgM | Rapid test | 70.0 |
| Colombia, Monteria | Mattar et al[4] | 1368 | August 2020 | IgG/IgM/IgA | Commercial test (ELISA) | 55.3 |
| Israel | Reicher et al[5] | 54 357 | June-Sept 2020 | IgG anti-Sc | Commercial test (Diasorin) | 4.6 |
| South Sudan (Juba) | Wiens et al[6] | 2214 | August-September 2020 | IgG anti-S-RBDd | Commercial test (Quantitative ELISA) | 22.3 |
| Oman | Al-Abri et al[7] | 4064 | November 2020 | IgG anti-S | Commercial test (Diasorin) | 22.0 |
| Sri Lanka | Jeewandara et al[8] | 2547 | January 2021 | IgA, IgM, IgG anti-RBD | Commercial test (Wantai SARS-CoV-2 Ab ELISA) | 24.5 |
| Sierra Leone | Barrie et al [9] | 1893 | March 2021 | IgG/IgM | Commercial Rapid test | 2.6 |
| Zimbabwe | Fryatt et al [10] | 2340 | Feb-April 2021 | IgG anti-Nb | Commercial test Roche Elecsys | 53.0 |

a: United Arab Emirates

b: Immunoglobuline G antibodies to the nucleocapsid protein

c: Immunoglobuline G antibodies to the the spike protein

d: Immunoglobuline G antibodies to the receptor-binding domain of the spike protein

References:

1. Le Vu S, Jones G, Anna F, Rose T, Richard J-B, Bernard-Stoecklin S, et al. Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance. Nat Commun. 2021;12(1):3025.

2. Alsuwaidi AR, Al Hosani FI, Al Memari S, Narchi H, Abdel Wareth L, Kamal H, et al. Seroprevalence of COVID-19 infection in the Emirate of Abu Dhabi, United Arab Emirates: a population-based cross-sectional study. Int J Epidemiol. 2021;50(4):1077-1090

3. Álvarez-Antonio C, Meza-Sánchez G, Calampa C, Casanova W, Carey C, Alava F, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study. Lancet Glob Health. 2021;9(7):e925–31.

4. Mattar S, Alvis-Guzman N, Garay E, Rivero R, García A, Botero Y, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries? Open Forum Infect Dis. 2020;7(12):ofaa550.

5. Reicher S, Ratzon R, Ben-Sahar S, Hermoni-Alon S, Mossinson D, Shenhar Y, et al. Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel. Eur J Epidemiol. 2021;36(7):727–34.

6. Wiens KE, Mawien PN, Rumunu J, Slater D, Jones FK, Moheed S, et al. Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 IgG in Juba, South Sudan, 2020. Emerg Infect Dis. 2021;27(6):1598–606.

7. Al-Abri SS, Al-Wahaibi A, Al-Kindi H, Kurup PJ, Al-Maqbali A, Al-Mayahi Z, et al. Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys. Int J Infect Dis. 2021;112:269–77.

8. Jeewandara C, Guruge D, Abyrathna IS, Danasekara S, Gunasekera B, Pushpakumara PD, et al. Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka. Front Public Health. 2021;9:724398

9. Barrie MB, Lakoh S, Kelly JD, Kanu JS, Squire JS, Koroma Z, et al. SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey. BMJ Glob Health. 2021;6(11):e007271.

10. Fryatt A, Simms V, Bandason T, Redzo N, Olaru ID, Ndhlovu CE, et al. Community SARS-CoV-2 seroprevalence before and after the second wave of SARS-CoV-2 infection in Harare, Zimbabwe. EClinicalMedicine. 2021;41:101172.